Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 215503
Company: HIKMA
Company: HIKMA
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | AP1 | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 12/23/2024 | ORIG-1 | Approval | STANDARD |
Letter (PDF)
Review (PDF) |
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215503Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215503Orig1s000edt.pdf |
LIRAGLUTIDE
SOLUTION;SUBCUTANEOUS; 18MG/3ML (6MG/ML)
TE Code = AP1
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 215245 | BIOCON PHARMA |
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 212552 | FRESENIUS KABI USA |
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 215503 | HIKMA |
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 215421 | LUPIN LTD |
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 218115 | NANJING KING FRIEND |
| LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | No | AP1 | 217590 | ORBICULAR |
| VICTOZA | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription | Yes | AP1 | 022341 | NOVO NORDISK INC |